Brokerages expect Bristol-Myers Squibb (NYSE:BMY) to report $1.83 earnings per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Bristol-Myers Squibb’s earnings, with the highest EPS estimate coming in at $1.96 and the lowest estimate coming in at $1.76. Bristol-Myers Squibb posted earnings per share of $1.72 in the same quarter last year, which indicates a positive year-over-year growth rate of 6.4%. The company is expected to issue its next earnings report on Thursday, May 6th.
On average, analysts expect that Bristol-Myers Squibb will report full year earnings of $7.43 per share for the current fiscal year, with EPS estimates ranging from $7.30 to $7.62. For the next fiscal year, analysts forecast that the business will post earnings of $7.99 per share, with EPS estimates ranging from $7.78 to $8.26. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Bristol-Myers Squibb.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Wednesday, February 3rd. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.42 by $0.04. The business had revenue of $11.07 billion during the quarter, compared to the consensus estimate of $10.74 billion. Bristol-Myers Squibb had a negative net margin of 0.11% and a positive return on equity of 27.48%. Bristol-Myers Squibb’s quarterly revenue was up 39.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.22 EPS.
Several equities analysts recently commented on BMY shares. Sanford C. Bernstein reiterated a “market perform” rating and set a $72.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, November 10th. Gabelli cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Friday, November 6th. TheStreet upgraded shares of Bristol-Myers Squibb from a “c+” rating to a “b” rating in a research note on Monday, December 7th. Societe Generale upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $76.00 price objective for the company in a research note on Monday, November 16th. Finally, Smith Barney Citigroup increased their price objective on shares of Bristol-Myers Squibb from $73.00 to $77.00 in a research note on Monday, November 30th. Five research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $73.75.
NYSE:BMY traded down $0.46 during trading hours on Tuesday, hitting $60.53. 474,877 shares of the company traded hands, compared to its average volume of 12,958,490. The stock has a market capitalization of $135.62 billion, a price-to-earnings ratio of -554.40, a P/E/G ratio of 1.00 and a beta of 0.67. Bristol-Myers Squibb has a twelve month low of $45.76 and a twelve month high of $67.16. The firm has a 50-day moving average of $62.59 and a 200 day moving average of $70.48. The company has a current ratio of 1.67, a quick ratio of 1.58 and a debt-to-equity ratio of 0.82.
The business also recently disclosed a quarterly dividend, which was paid on Monday, February 1st. Shareholders of record on Monday, January 4th were issued a dividend of $0.49 per share. The ex-dividend date was Thursday, December 31st. This represents a $1.96 dividend on an annualized basis and a yield of 3.24%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.45. Bristol-Myers Squibb’s dividend payout ratio is currently 41.79%.
A number of large investors have recently modified their holdings of BMY. Fiduciary Planning LLC bought a new stake in Bristol-Myers Squibb during the 3rd quarter worth about $25,000. Retirement Group LLC bought a new stake in Bristol-Myers Squibb during the 4th quarter worth about $27,000. Orion Capital Management LLC bought a new stake in Bristol-Myers Squibb during the 4th quarter worth about $28,000. Perennial Advisors LLC bought a new stake in Bristol-Myers Squibb during the 4th quarter worth about $29,000. Finally, Founders Capital Management bought a new stake in Bristol-Myers Squibb during the 4th quarter worth about $31,000. 72.41% of the stock is currently owned by hedge funds and other institutional investors.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. The company's products include Opdivo for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.
Further Reading: What is the price-to-earnings growth (PEG) ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.